Acrivon Therapeutics (ACRV) News Today → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free ACRV Stock Alerts $8.47 -1.03 (-10.84%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAcrivon Therapeutics: Strong Buy Recommendation on Impressive AP3 Platform and ACR-368 Data Validationmarkets.businessinsider.com - April 25 at 7:59 PMAcrivon Therapeutics: Strong Buy on Impressive Clinical Outcomes and Market Potentialmarkets.businessinsider.com - April 25 at 7:59 PMAcrivon Therapeutics (NASDAQ:ACRV) Price Target Raised to $17.00 at JMP Securitiesmarketbeat.com - April 25 at 1:40 PMmarketbeat.com - April 25 at 9:47 AMmarketbeat.com - April 25 at 9:38 AMAcrivon Therapeutics (NASDAQ:ACRV) Earns "Buy" Rating from HC Wainwrightmarketbeat.com - April 25 at 8:09 AMAcrivon Therapeutics’ shares climb 14% on plans to present cancer-test datamsn.com - April 24 at 9:04 PMAcrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Eventglobenewswire.com - April 24 at 4:01 PMAcrivon Therapeutics, Inc. (ACRV)finance.yahoo.com - April 20 at 7:50 PMAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Recommendation of "Buy" by Brokeragesamericanbankingnews.com - April 20 at 4:18 AMAcrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316finance.yahoo.com - April 16 at 11:45 PMAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Significant Increase in Short Interestamericanbankingnews.com - April 16 at 5:14 AMAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Major Shareholder Perceptive Advisors Llc Buys 2,353,000 Sharesamericanbankingnews.com - April 16 at 4:16 AMAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Major Shareholder Buys $20,000,500.00 in Stockinsidertrades.com - April 16 at 4:14 AMAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Major Shareholder Acquires $20,000,500.00 in Stockmarketbeat.com - April 15 at 12:38 PMEquities Analysts Issue Forecasts for Acrivon Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:ACRV)marketbeat.com - April 12 at 6:09 AMBuy Rating Affirmed for Acrivon Therapeutics on Promising Drug Pipeline and Solid Financialsmarkets.businessinsider.com - April 10 at 8:44 PMAcrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368globenewswire.com - April 10 at 8:00 AMAcrivon To Privately Place $130 Mln Of Shares; Stock Soars In Pre-marketmarkets.businessinsider.com - April 9 at 12:39 PMAcrivon Therapeutics Stock Is Soaring Tuesday: What's Going On?msn.com - April 9 at 12:39 PMACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boostinvestorplace.com - April 9 at 10:32 AMAcrivon Therapeutics Announces $130 Million Private Placement Financingglobenewswire.com - April 9 at 7:00 AMLADENBURG THALM/SH SH Lowers Acrivon Therapeutics (NASDAQ:ACRV) Price Target to $14.00marketbeat.com - April 5 at 11:38 AMBMO Capital Markets Reiterates Outperform Rating for Acrivon Therapeutics (NASDAQ:ACRV)marketbeat.com - April 1 at 1:38 PMBuy Rating on Acrivon Therapeutics: Anticipated Clinical Validation and Strong Financial Positionmarkets.businessinsider.com - April 1 at 7:03 AMBuy Rating Affirmed for Acrivon Therapeutics Amid Anticipated Clinical Updates and Platform Potentialmarkets.businessinsider.com - March 29 at 1:08 PMAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Expected to Earn Q1 2024 Earnings of ($0.88) Per Sharemarketbeat.com - March 29 at 8:16 AMBuy Rating Justified by Acrivon Therapeutics’ Clinical Progress and Market Potentialmarkets.businessinsider.com - March 29 at 3:06 AMAcrivon Therapeutics: Strong Buy on Promising Clinical Trials and Innovative Drug Developmentmarkets.businessinsider.com - March 29 at 3:06 AMACRV Stock Earnings: Acrivon Therapeutics Misses EPS for Q4 2023investorplace.com - March 28 at 2:01 PMHC Wainwright Reaffirms "Buy" Rating for Acrivon Therapeutics (NASDAQ:ACRV)marketbeat.com - March 28 at 1:46 PMAcrivon Therapeutics, Inc: Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlightsfinanznachrichten.de - March 28 at 12:05 PMAcrivon Therapeutics: Q4 Earnings Insightsbenzinga.com - March 28 at 12:05 PMAcrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlightsglobenewswire.com - March 28 at 8:00 AMAcrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316globenewswire.com - March 5 at 4:30 PMAcrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directorsfinance.yahoo.com - March 4 at 12:34 PMJMP Securities Initiates Coverage of Acrivon Therapeutics (ACRV) with Market Outperform Recommendationmsn.com - March 2 at 8:12 AMAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Recommendation of "Buy" from Brokeragesmarketbeat.com - March 1 at 9:22 AMAcrivon Therapeutics (NASDAQ:ACRV) Coverage Initiated by Analysts at JMP Securitiesmarketbeat.com - March 1 at 7:41 AMUnlocking Value in Precision Oncology: Acrivon Therapeutics’ Unique Platform and Promising Pipelinemarkets.businessinsider.com - March 1 at 5:49 AMAcrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conferenceglobenewswire.com - February 27 at 8:00 AMAcrivon Therapeutics Welcomes New Board Member Dr. Magovcevic-Liebischmsn.com - February 9 at 9:39 AMAcrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directorsfinance.yahoo.com - February 8 at 9:36 AMAcrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conferencefinance.yahoo.com - February 6 at 9:28 AMAcrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 4 at 8:15 AMAcrivon Therapeutics appoints Jean-Marie Cuillerot as Chief Medical Officermsn.com - January 3 at 12:49 PMAcrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officerfinance.yahoo.com - January 3 at 12:49 PMAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Rating of "Buy" from Brokeragesmarketbeat.com - January 2 at 2:20 AMTravere Therapeutics, Replimune among healthcare moversmsn.com - December 5 at 2:12 PMmarketbeat.com - December 4 at 4:03 PM Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address “Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers. Find out why right here (and see what you can do to get in too with just a few dollars). ACRV Media Mentions By Week ACRV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACRV News Sentiment▼0.320.41▲Average Medical News Sentiment ACRV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACRV Articles This Week▼111▲ACRV Articles Average Week Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Merrimack Pharmaceuticals News Today Immutep News Today Theseus Pharmaceuticals News Today ProQR Therapeutics News Today Syros Pharmaceuticals News Today NGM Biopharmaceuticals News Today Vistagen Therapeutics News Today Kinnate Biopharma News Today Assembly Biosciences News Today vTv Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACRV) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
